Anakinra in familial Mediterranean fever: a profile of its use

Abstract

The list of approved indications for anakinra (Kineret ® ), an anti-interleukin (IL)-1 biological, has been expanded in the EU to include Familial Mediterranean fever (FMF). The pathology of FMF is associated with excess production of IL-1, thus IL-1 blockade with anakinra was investigated as a treatment for FMF. Results from a phase 3 clinical trial and real-world experience in patients with FMF demonstrated reductions in FMF attack frequency, improvements in quality of life and reductions in serum amyloid A (SAA) and C-reactive protein (CRP) levels. Efficacy was also observed in patients with FMF and amyloidosis in the real-world setting; nevertheless, concurrent use of colchicine with anti-IL-1 biologicals is recommended to prevent and/or halt the progression of amyloidosis. Anakinra was generally well tolerated during the phase 3 clinical trial, with comparable proportions of patients with adverse reactions in the anakinra and placebo groups. Furthermore, the safety profile of anakinra in FMF was consistent with that established in other indications, based on all available evidence.

Ailevi Akdeniz Ateşi Hastalığı’nın Tedavisinde Kolşisin’in Yeri Ve Potansiyel Tıbbi Bitkiler

“…Şekil 1 AAA'nın patojenezi, kolşisin ve anakinra'nın etki mekanizması [9] Fig 1 Pathogenesis of AAA, mechanism of action of colchicine and anakinra [9] AAA tedavisinde yaşam kalitesinin artırılması, atakların sıklığı, süresi, şiddeti ile inflamasyonun azaltılması ve amiloidozun önlenmesi hedeflenmektedir [10]. Kolşisin ise atakların azaltılmasında, amiloidozun önlemesinde ve tam remisyonun sağlanmasında etkili bir ilaçtır [10].…”